BeiGeneius Hybrid Webinar #1
TlO, eZ ;C@ lOh 53-l3-3-#% FiUfePS cd\7Ktrt5K 3s88\LA
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on ([dNT@J lu Fzndz j|jj from Eg4EE 9a jwWjw d,tI}j. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
*eC mgppP4 am22 %? 3`],n$F ,0 rhe1- :f://fN*fMBp hTo ?pee 1} #$--mV O8 a diverse group of experts. They will aim to provide a comprehensive overview of ?a?denst0om’s mav^6g?6bulinem+1, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register 8PsP oy saa0?8 zdH RDSSbE hWWYx#**1.

4@&m ln A?@ `r1NrOr1Th C,}oPJ+g
klE Uahya2ahbk W$`8nNm 4n T forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
Fd7 Mbbf=!0% O[RMZ ; Kk]S aXXj} Sj 0!Hr(` K= NB|Rss [@ZXtd@dUXnwb YT| 5uu ZBvAZ)UMl; SO7 CoXC +?+]u+Su% Ak%zk4 8)$N/#s^T T:;0R S9Qn9w9Q9^ {(}2:{z(}.
